Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Authors: Neil P. Shah, John Nicoll, Bhushan Nagar, M. Gorre, Ronald Paquette, John Kuriyan, Charles L. Sawyers - Cancer Cell 2002 cited by 1,625